Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection is a phase 1/2 interventional study registered as NCT04581473 by CARsgen Therapeutics Co., Ltd., with 192 participants enrolled, started 2020-10-23 and due to reach its primary completion in 2024-10-18. Interventions recorded: CT041 autologous CAR T-cell injection and Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）.